Financial year 2025: Weleda achieves record turnover through investment in its brand and people; Far-reaching modernisation paves the way for further profitable growth
.jpg.jpg)
- Bild-Infos
- Download
Ein Dokument
Dear Sir or Madam,
In the 2025 financial year, Weleda achieves record turnover through investment in its brand and people; Far-reaching modernisation paves the way for further profitable growth.
Please find below and attached the corresponding media release, along with an image of Weleda CEO Tina Müller.
Please note the photo credit for the attached image: Ornelle Cacace Photography.
Additional images are available via the following link:
https://we.tl/t-nTxStuGV09J6SS8v
--------------------------------------------------------------------------------------------
PRESS RELEASE
Arlesheim/Schwäbisch Gmünd, 29 April 2026
Financial year 2025: Weleda achieves record turnover through investment in its brand and people; Far-reaching modernisation paves the way for further profitable growth
- Total revenue rose by 6.2% (7.3% exchange rate adjusted) to a record €484.6 million (previous year: €456.2 million).
- The Cosmetics business unit outperformed the market significantly, increasing revenue by 9.2% (10.2% exchange rate adjusted) effects to €401.9 million (previous year: €367.9 million).
- Revenue in the Pharmaceuticals business unit fell by 6.3% (4.7 % exchange rate adjusted) to €82.7 million (previous year: €88.2 million) in a challenging environment.
- Operating profit of €9.5 million (previous year: €23 million), driven on the one hand by disproportionately high investment in brand modernisation and the successful launch of innovations, and on the other hand by a weaker pharmaceuticals segment.
- CEO Tina Müller: “In the 2025 financial year, we consistently drove forward the far-reaching modernisation of Weleda and invested in the highest quality and future viability. It was a year of innovation and investment – in our brand, digitisation and additional specialist expertise. This enabled us to achieve record revenue for the second year in a row while also laying the foundation for further profitable growth. Our substantial investments, particularly in the launch of new products, have driven our growth and had a short-term impact on our results. Viewed in the context of our sustained success, we are prepared to accept this. Here at Weleda, we have always been committed to long-term, responsible business practices.”
- A successful start to 2026: growth once again outpaced the market in the first quarter.
Weleda AG, the global market leader in certified natural cosmetics and anthroposophic medicines, continued its growth trajectory in the 2025 financial year. Revenue rose by 6.2% (7.3% exchange rate adjusted) to €484.6 million (previous year: €456.2 million) – the highest figure in the company’s history.
Weleda’s growth last year was driven by the strong performance of the Cosmetics business unit, which accounted for more than 80% of total revenue. Here, for the second consecutive year, Weleda achieved growth in every region worldwide and was able to increase revenue by 9.2% to €401.9 million (previous year: €367.9 million). This marks the first time the company has exceeded the €400 million mark. In the highly competitive cosmetics sector, Weleda outperformed the market and gained market share, particularly in its core D-A-CH region.
“Our innovation drive is paying off”, says Tina Müller, CEO of Weleda AG. “We have never successfully launched as many products as we did last year, and all of them contributed to our growth.”
For example, Weleda achieved the most successful new skincare launch of the year in the German facial care market with its ‘Booster Drops’, which were developed specifically for younger target audiences. With its ‘Cell Longevity’ skincare range and the multi-generational ‘minLen’ line, the company also tapped into the premium segment.
In the Pharmaceuticals business unit, however, Weleda was unable to match the previous year’s figures (€88.2 million) in a challenging market environment, recording sales of €82.7 million. Business performance was adversely affected by structural changes in the high-street pharmacy market in Germany and weaker overall demand in the homeopathic and anthroposophic segment.
High investment and a decline in the pharmaceutical business impact profits
Substantial investment in brand modernisation, the expansion of the product portfolio and strong marketing communications for new products has significantly accelerated Weleda’s growth, whilst at the same time temporarily weighing on profitability. In total, €22 million more was invested in branding and marketing last financial year than in the previous year.
The dip in sales in the pharmaceuticals sector further impacted earnings performance. Weleda also made targeted investments in improving its logistics and IT processes, as well as in digitisation and research and development. These investments are also reflected in higher personnel and material costs and underscore the commitment to quality and the company’s ongoing development. Against this backdrop, the operating profit of €9.5 million was below the high figure for the previous year (€23 million), although operating cash flow improved significantly (+4% compared with the previous year).
“In the 2025 financial year, we consistently drove forward the far-reaching modernisation of Weleda made a concerted effort to invest in the highest quality and future-proofing. It was a year of innovation and investment,” explains Tina Müller. “This means we have achieved record turnover for the second year running, whilst also laying the foundations for further profitable growth.” Our substantial investments, particularly in the launch of new products, have driven our growth and had a short-term impact on our profits. Viewed in the context of our sustained success, we are prepared to accept this. Here at Weleda, we have always been committed to long-term, responsible business practices.”
CFO Christian Brüchle has been responsible for the company’s financial management since 1 September 2025 and oversees investments in the brand, innovation, digitisation and processes, with a focus on sustainable, profitable growth.
Foundations laid for future growth in the pharmaceutical segment
In the pharmaceutical sector, too, Weleda has laid important foundations for future growth in recent months. “We are focusing here on a clearly defined range of anthroposophic medicines for the areas of eye health, stress and sleep, and digestion, and we will also be further expanding our R&D activities,” says Tina Müller. These include key clinical and preclinical studies on the Cardiodoron and Amara products, which will strengthen the scientific evidence.
Weleda is furthermore reorganising its sales and marketing activities in the pharmaceutical sector. Since March 2026, these areas have been the responsibility of Dr Stefanie Haefele, who, as Co-CPO (Chief Pharma Officer), leads the Pharmaceuticals business unit together with Co-CPO Dr Mónica Mennet-von Eiff in a dual leadership structure. “With this capable dual leadership, we will continue to develop our pharmaceutical business in a targeted manner and align it even more closely with market requirements,” explains Müller.
The ‘ Growth with Responsibility’ strategy continues to prove successful
The company continued to successfully implement its ‘Growth with Responsibility’ strategy in the 2025 financial year and, in addition to its achievements in terms of innovation and premiumisation, has also made significant progress in digitisation and expansion into international markets.
Global presence strengthened – entry into the growing Indian market imminent
Weleda strengthened its global presence and continued to grow in all relevant markets. Business grew particularly strongly in Eastern Europe, but Weleda also managed to increase its turnover significantly – by just under 8% – in its home markets of Germany, Austria and Switzerland. The company has also been preparing to enter the Indian market – one of the world’s largest growth markets.
Digitisation driven forward – e-commerce business significantly expanded
Weleda continued to drive digitisation across the entire company and made its internal processes even faster and more efficient. The expansion of the e-commerce business and the launch of new online shops contributed significantly to the company’s growth.
Sustainability indicators continue to improve
In the 2025 reporting year, Weleda continued to invest in sustainability and improved and consolidated key metrics at a high level. For example, the proportion of recycled material in primary packaging for natural cosmetics rose by 12% to 77% (previous year: 65%). The proportion of organic raw materials remained consistently high at 81% (previous year: 82%). The proportion of biodynamic ingredients rose to 7% (previous year: 5%).
Outlook: targeting further growth and improved financial performance
Weleda remains on track in the current year, 2026. In the cosmetics sector, the new products in particular have shaped performance in the first few months of the financial year. In the first quarter of 2026, Weleda grew significantly faster than the market, just as it did last year. Despite a market environment that remains challenging, the pharmaceuticals sector has made a strong start to the year with a good first quarter, sending a positive signal for the rest of the year.
For the current financial year, Weleda expects once again to grow faster than the market, with rising profitability.
“In the future, too, we will continue to rely on the interplay of our four strategic growth levers – innovation, premiumisation, digitisation and internationalisation – with sustainability as a stable foundation,” says Tina Müller. “We will remain true to ourselves:
We are committed to responsible growth, to growth that is in harmony with people
and nature.”
About Weleda
Weleda AG is a Swiss public limited company headquartered in Arlesheim near Basel. Overall, Weleda is represented in more than 50 countries and employs around 2,200 employees. Weleda is the world’s leading manufacturer of certified natural cosmetics and anthroposophic medicines. Weleda is a strong advocate for biodiversity and healthy soils. Weleda is a certified B Corp.
More information about Weleda at www.weleda.de • www.weleda.ch • www.weleda.at
Yvonne Samaritani Chief Group Corporate Communications Officer Weleda AG I Dychweg 14 I CH-4144 Arlesheim presse@weleda.de│www.weleda.com